Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus
SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health …

Abstract Coronavirus Disease 19 (COVID-19) is associated with high morbidity and mortality
rates globally, representing the greatest health and economic challenge today. Several …

The viral infection by SARS-CoV-2 has irrevocably altered the life of the majority of human
beings, challenging national health systems worldwide, and pushing researchers to rapidly …

Coronavirus disease 2019 (COVID-19) pneumonia caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality in pandemic …

Background Glucocorticoids are widely used in the treatment of various pulmonary
inflammatory diseases, but they are also often accompanied by significant adverse …

Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is characterized by a wide spectrum of symptom …

Prolonged, low-dose glucocorticoids (GCs) have shown the highest efficacy among
pharmacological and non-pharmacological treatments for COVID-19. Despite the World …

Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced
COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in …

The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on
the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical …

The underlying cause of many complications associated with severe COVID-19 is attributed
to the inflammatory cytokine storm that leads to acute respiratory distress syndrome (ARDS) …